130 related articles for article (PubMed ID: 38194911)
1. Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?
Shaitelman SF; Woodward WA
Cancer Cell; 2024 Jan; 42(1):10-12. PubMed ID: 38194911
[TBL] [Abstract][Full Text] [Related]
2. Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.
Deng J; Thennavan A; Shah S; Bagdatlioglu E; Klar N; Heguy A; Marier C; Meyn P; Zhang Y; Labbe K; Almonte C; Krogsgaard M; Perou CM; Wong KK; Adams S
Breast Cancer Res Treat; 2021 Jan; 185(1):85-94. PubMed ID: 32949350
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.
Sharma P; Stecklein SR; Yoder R; Staley JM; Schwensen K; O'Dea A; Nye L; Satelli D; Crane G; Madan R; O'Neil MF; Wagner J; Larson KE; Balanoff C; Kilgore L; Phadnis MA; Godwin AK; Salgado R; Khan QJ; O'Shaughnessy J
JAMA Oncol; 2024 Feb; 10(2):227-235. PubMed ID: 37991778
[TBL] [Abstract][Full Text] [Related]
4. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
Zhao Y; Schaafsma E; Cheng C
Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
Cortes J; Haiderali A; Huang M; Pan W; Schmid P; Akers KG; Park JE; Frederickson AM; Fasching PA; O'Shaughnessy J
BMC Cancer; 2023 Aug; 23(1):792. PubMed ID: 37612624
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
[TBL] [Abstract][Full Text] [Related]
7. Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1.
Tan H; Liu J; Huang J; Li Y; Xie Q; Dong Y; Mi Z; Ma X; Rong P
J Transl Med; 2023 Jul; 21(1):462. PubMed ID: 37438720
[TBL] [Abstract][Full Text] [Related]
8. Tumor Microenvironment Can Predict Chemotherapy Response of Patients with Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Kim D; Yu Y; Jung KS; Kim YH; Kim JJ
Cancer Res Treat; 2024 Jan; 56(1):162-177. PubMed ID: 37499695
[TBL] [Abstract][Full Text] [Related]
9. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
Fisher TB; Saini G; Rekha TS; Krishnamurthy J; Bhattarai S; Callagy G; Webber M; Janssen EAM; Kong J; Aneja R
Breast Cancer Res; 2024 Jan; 26(1):12. PubMed ID: 38238771
[TBL] [Abstract][Full Text] [Related]
10. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract][Full Text] [Related]
11. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.
Shiao SL; Gouin KH; Ing N; Ho A; Basho R; Shah A; Mebane RH; Zitser D; Martinez A; Mevises NY; Ben-Cheikh B; Henson R; Mita M; McAndrew P; Karlan S; Giuliano A; Chung A; Amersi F; Dang C; Richardson H; Shon W; Dadmanesh F; Burnison M; Mirhadi A; Zumsteg ZS; Choi R; Davis M; Lee J; Rollins D; Martin C; Khameneh NH; McArthur H; Knott SRV
Cancer Cell; 2024 Jan; 42(1):70-84.e8. PubMed ID: 38194915
[TBL] [Abstract][Full Text] [Related]
12. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
13. Single-cell RNA-sequencing uncovers compound kushen injection synergistically improves the efficacy of chemotherapy by modulating the tumor environment of breast cancer.
Liu X; Bai M; Li H; Ye P; Duan X; Wu C; Huang Z; Lu S; Zhang J; Zhao Z; Guo F; You R; Qin W; Wang W; Han A; Shen L; Wang Y; Zhao Z; Luo H; Wu J
Front Immunol; 2022; 13():965342. PubMed ID: 36389835
[TBL] [Abstract][Full Text] [Related]
14. Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer.
Palakurthi B; Fross SR; Guldner IH; Aleksandrovic E; Liu X; Martino AK; Wang Q; Neff RA; Golomb SM; Lewis C; Peng Y; Howe EN; Zhang S
Nat Commun; 2023 Apr; 14(1):2109. PubMed ID: 37055410
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
16. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.
van den Ende NS; Nguyen AH; Jager A; Kok M; Debets R; van Deurzen CHM
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769287
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
Varma R; Wright M; Abraham J; Kruse M
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
[TBL] [Abstract][Full Text] [Related]
18. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
19. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
[TBL] [Abstract][Full Text] [Related]
20. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]